Drugs / MFGS-p47phox
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00001476 Background | Jun 1995 → Dec 2010 | chronic granulomatous disease, infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MFGS-p47phox | “Cultured CD34+ progenitors will be transduced on each of 3 or 4 days with either MFGS-p47phox or MFGS-gp91phox retrovirus vectors.” NCT00001476 ↗ |
| Route | Intravenous | “intravenously infused, gene corrected stem cells” NCT00001476 ↗ |